We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The main challenge for BNT-162b2 is the ultra-cold storage requirement of -80°C. The vaccine is likely to suffer poor uptake in countries that have limited cold-chain logistics.